Ultrahuman's small piece of finger-worn hardware is the entry point to a much larger business ambition. The Bengaluru health-technology company, which sells smart rings that collect signals used to track sleep, movement and recovery, announced $70 million of financing on September 3 to expand its connected health products.
The ring gathers measurements over time rather than waiting for a user to start an activity. Ultrahuman pairs that wearable with separate products for blood testing, glucose monitoring and the home environment. Its stated goal is to bring different kinds of information into the same experience: sleep measurements, for example, can be considered alongside metabolic data rather than appearing as unrelated numbers in separate services.
The commercial offering includes hardware and optional software purchases. On its PowerPlugs product page, Ultrahuman describes both free tools and paid add-ons, while saying those additions do not restrict the core app. A free caffeine feature suggests timing and cutoffs; other modules offer more specialized experiences. This gives the company a way to offer additional services to an existing ring owner without requiring every customer to buy the same software package.
It is also building a research layer around the installed devices. The company says Pulsomics, introduced in 2026, lets users opt into studies of subjects including sleep needs and glucose metabolism. It describes Ring PRO as moving more computation onto the wearable. These are product and research directions, not evidence that a ring can diagnose every condition or that proposed capabilities have already achieved clinical validation.
The announced investors include Qualcomm Ventures, Labcorp, Alpha Wave, Blume, Nexus and Alteria. CEO Mohit Kumar told TechCrunch that the round contains $65 million of primary equity and $5 million of debt. Captables counts the disclosed primary-equity portion in its funding-round tally. The company's release says the capital will support sensing technology, health algorithms, clinical research and broader distribution.
Captables' read: the important shift is from selling a tracker to earning an ongoing role in how customers interpret their health information. Optional software and additional measurements could deepen that relationship. Whether they do will depend on usefulness, credible validation and the willingness of customers to keep engaging—not just the quantity of signals a device can collect.